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Abstract Nicotine has several health hazards regarding carcinogenic potential. It also imparts 
increased risk for respiratory, cardiovascular, and gastrointestinal disorders. Several 
mechanisms have been proposed for the carcinogenic potential, including effects on cell 
proliferation, inducing oxidative stress, DNA mutation, or inhibition of apoptosis. The 
cotinine metabolite is generally thought to have effects similar to nicotine in some 
experimental systems. 
The purpose of this study was to assess the nicotine and cotinine cytotoxicity on 
MRC-5 lung fibroblasts. The pulmonary fibroblasts were treated with various 
concentrations of nicotine or cotinine (in the range 1 µM – 2 mM) for 24 or 48 h and 
analyzed for cell viability by MTT test. 
The results indicated that high nicotine concentrations (2 mM) induced marked cell 
death (about 50%) in MRC-5 cell line. Cotinine showed lower toxicity than nicotine on 
the MRC-5 cells. In contrast to nicotine treatment, cells treated with cotinine continued 
to proliferate after the 48h incubation period. 
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Highlights ✓ At concentrations similar to the levels observed in the plasma of smokers, nicotine and 
cotinine were not cytotoxic on MRC-5 cell line  
✓ Higher concentrations (2mM) of both nicotine and cotinine decreased the viability of 
MRC-5 cells.  
✓ Nicotine proved to be more cytotoxic than cotinine. Unlike nicotine, the proliferative 
capacity of MRC-5 cells is maintained after 48 hours of cotinine treatment.  
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Introduction 
Smoking is the only cause of premature death that 
can be totally prevented. Morbidity induced by tobacco 
smoking refers in particular to diseases of the respiratory 
system and the cardiovascular system. In addition, 
increased prevalence of cancer at different levels in the 
body, urinary tract damage, gastrointestinal disorders, 
ocular damage, endocrine and metabolic alterations, and 
adverse effects on pregnancy have been reported. An 
alarming aspect is that smoking also affects the health of 
non-smokers who are passively exposed to tobacco 
smoke (1, 2). 
Nicotine alkaloid is the major addictive component 
of tobacco. Nicotine is a highly toxic compound that 
exerts its effects on almost every organ and system in 
the body. It is absorbed through the entire respiratory 
tract, through the oral and nasal mucosa, into the 
gastrointestinal tract, and even through the skin. In vivo, 
nicotine is extensively metabolized by cytochrome P450 
in the liver, to the major metabolite cotinine (Figure 1). 
Cotinine metabolite has a relatively long half-life (~17 
h) compared to nicotine (1–2 h) and it is used as a 
biomarker for smoking, including passive smoking 
(3,4). 
 
Figure 1. Oxidative biotransformation of 
nicotine to cotinine 
The carcinogenic potential of nicotine is supported 
by current studies. Many types of cancers, including 
small-cell and non-small-cell lung carcinomas, head and 
neck, gastric, pancreatic, colon, breast, cervical, urinary, 
bladder, and kidney cancers have been associated with 
nicotine (5). 
Several studies indicate that nicotine is toxic and 
addictive, but it is not carcinogenic (6). 
Current in vitro and in vivo studies demonstrate that 
nicotine and its main metabolite cotinine have tumor-
promoting activities. In addition, tobacco smoke 
contains a variety of proved carcinogens including 
polycyclic aromatic hydrocarbons (i.e. 3,4- 
benzo(a)pyrenes), and tobacco-specific nitrosamines, 
such as 4-(methylnitrosamino)-1-(3-pyridyl)-1-
butanone (NNK) and N’-nitrosonornicotine (NNN) (7). 
The current research is focused on the molecular 
mechanisms by which nicotine and tobacco smoke can 
initiate tumor formation, influence cell cycle 
progression and proliferation, and promote tumor 
progression in multiple cancer types (7). The potential 
of nicotine in inducing DNA mutations as a step towards 
cancer initiation is still controversially discussed (8).  
Nicotine was shown to have an important role in 
regulating cellular processes such as proliferation, 
differentiation, and migration. In normal cells, nicotine 
can stimulate mechanisms consistent with cell 
transformation and the early stages of cancer 
development (9).  
On in vitro systems, it has been demonstrated that 
nicotine increased cell proliferation, inhibited apoptosis, 
stimulated cancer cell growth, and enhanced or inhibited 
angiogenesis. Nicotine was also reported to promote 
tumor growth and metastasis in cancer xenograft models 
(10).  
Nicotine exerts its effects by activating the nicotinic 
acetylcholine receptors (nAChRs) that are expressed in 
neurons and neuromuscular junctions and in a wide 
variety of non-neuronal cells, including those of 
epithelial and endothelial origin. 
Nicotine has been demonstrated to have tumor-
promoting properties by activating the nAChRs; this 
may result in activation of several signaling pathways 
that can have tumorigenic effects. It has been shown that 
nicotine (at concentrations similar to those in the 
bloodstream of smokers, ranged from 10 nmol/L to 10 
μmol/L) or tobacco-specific nitrosamines such as NNK 
could induce proliferation in various in vitro cell culture 
models, and this effect could be canceled by nAChR 
antagonists (7). 
Recent studies demonstrated that nicotine induces 
multiple cancer cell proliferation via α7-nAChR 
subunit. Thus, nicotine was shown to induce a dose-
dependent increase in proliferation of lung cancer cells, 
breast cancer cells, and pancreatic cancer cells via α7-
nAChRs-mediated signal transduction pathways (11). In 
addition, nicotine induced epithelial-to-mesenchymal 
transition (EMT) in breast and lung cancer (11). 
It has been demonstrated that nicotine induces cell 
proliferation via α7-nAChR subunit in mouse lung 
cancer and enhances the growth of tumors induced by 
tobacco carcinogens. In addition, nicotine promotes re-
growth and metastasis of tumors in mice (12). 
Nicotine was demonstrated to promote 
proliferation, invasion, and angiogenesis in tumor cells 
while inhibiting apoptosis (13).  
The cotinine metabolite was also shown to induce 
tumor promotion in human lung adenocarcinoma cells 
by inhibiting apoptosis and increasing cellular 
proliferation (14). 
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There are conflicting reports regarding the 
beneficial effects of nicotine and its main metabolite 
cotinine on the human body. Cotinine has been reported 
to have some pharmacologic activity that decreases 
vascular resistance, decreases blood pressure in animals, 
and affects cognitive performance (15). 
Nicotine (10-7 – 10-5 M) and cotinine (10-6 – 10-8 
M) exhibited neuroprotective properties in SH-SY5Y 
neuroblastoma cell line. Cotinine also protected against 
6-hydroxydopamine (6-OHDA)-induced cell damage in 
neuroblastoma cells (16). 
Studies have revealed the citotoxic effects of 
nicotine in different experimental systems while there 
are limited data regarding the citotoxic effects of 
cotinine. Nicotine exerts dose- and time-dependent 
cytotoxic effects on the mesenchymal stem cells derived 
from human periodontium (17). Nicotine and cigarette 
extract (CE) were demonstrated to induce cytotoxicity 
in human embryonic lung fibroblast, MRC-9 (18). 
The present study investigated the in vitro effects of 
nicotine and cotinine on proliferation of MRC-5 cell 
line, a diploid human cell culture line composed of 
fibroblasts derived from normal lung tissue of a 14-
week-old male fetus. 
 
Materials and method 
This study was performed on the continuous cell 
line of pulmonary fibroblasts MRC-5 (ATCC – 
American Type Culture Collection). According to the 
manufacturer's datasheet, these cells exhibit typical 
fibroblast morphology. 
To spread the culture, the cells were cultivated in 
Eagle's Minimum Essential Medium (EMEM) 
supplemented with 1 % antibiotic/antimichotic 
(ABAM) and 10% fetal bovine serum (SFB), put in 
sterile culture vials. The cells were incubated at 37°C, in 
humid atmosphere of 5% CO2 during the entire 
experimental period. In order to multiply, the cells 
adherent to the culture substrate were detached by 
means of enzimatic treatment with trypsin at 80 % 
confluency. Effectively, for the multiplication, the cells 
were detached from the culture surface with a solution 
of trypsin –EDTA. The cell sediment following the 
centrifugation was re-suspended in fresh culture 
medium, and the cell suspension was distributed in new 
culture vials.  
(-)-Nicotine (≥99%, Sigma-Aldrich) and (-)-
Cotinine (≥98%, Sigma-Aldrich) were used to prepare 
stock solutions in DMSO. Both nicotine and cotinine 
have been tested in the following dilutions: D1 = 2 mM, 
D2 = 1 mM; D3 = 750 µM; D4 = 500 µM; D5 = 100 
µM; D6 = 10 µM and D7 = 1 µM. 
For determining the optimal working dose and also 
for evaluating the proliferation of the cells under 
treatment with nicotine and cotinine, viability of the 
pulmonary fibroblasts MRC-5 was assessed. 
Cytotoxicity was determined by 3-(4,5-dimethylthiazol-
2-yl)-2,5 diphenyltetrazolium bromide (MTT) assay. 
The quantitative colorimetric MTT is based on the 
reduction of a yellow tetrazolium salt MTT to a blue-
violet formazan in the culture medium. The reduction 
reaction is made by the mytochondrial enzymes 
(especially hydrogenase succinate) and is an index of the 
cell/mitocondriale integrity. The formazan may be 
solubilised with izopropanol or DMSO, and the optic 
density (D.O.) of the solution obtained this way may be 
spectrophotometrically evaluated at 550nm. 
Briefly, the MRC-5 cells were seeded at a density 
of 103 cells/well into 96-well microtiter plates in three 
replicates and left for 24 hours to adhere. The next day, 
the culture medium was replaced with a fresh one, which 
contained different concentrations of nicotine or 
cotinine followed by incubation for 24 or 48 hours. After 
24 or 48 hours, the treatment was removed and the cell 
mono-layers were incubated for 4 h with a 1 mg/ml MTT 
solution in serum-free medium. The formazan crystals 
formed, in the meantime, by the active metabolic cells, 
have been solubilised in DMSO, and the D.O. of the 
resulting solution was determined at 550 nm. 
 
Statistics 
Quantitative data were processed and represented 
graphically by means of the soft GraphPad Prism 3.03. 
Data are expressed as mean ± SE (SEM). Grouped 
data were compared with one-way ANOVA with 
Bonferroni adjustment. P-values < 0.05 were considered 
statistically significant.  
 
Results 
Dose screening 
In order to examine if nicotine or cotinine is 
cytotoxic to MRC-5 cells, the cell line was treated with 
various concentrations of nicotine or cotinine in the 
range 1 µM – 2 mM for 24 h and analyzed for cell 
viability by MTT-assay. 
Dose screening for nicotine has shown that the use 
of a 2 mM dose lowers the viability of the cells to 50% 
compared to the non-treated control, and the treatment 
with concentrations which are lower or equal to 750 µM 
does not induce modifications of the cell viability 
(Figure 2). Lung fibroblast cell line MRC-5 was largely 
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unaffected by the nicotine treatment in the range of 
concentration 1 µM – 750 µM. Therefore, following the 
dose screening, the concentration of 1mM of nicotine 
was selected for the further study of the cell 
proliferation. 
 
Figure 2. The viability of the MRC-5 cells 
treated for 24h with nicotine D1 = 2 mM, D2 
= 1 mM, D3 = 750 µM, D4 = 500 µM, D5 = 
100 µM, D6 = 10 µM and D7 = 1 µM in 
culture medium  
The viability of the MRC-5 cells treated with 
cotinine was unaffected in the range of concentration 1 
µM – 1 mM (Figure 3). Cotinine showed lower toxicity 
than nicotine on the MRC-5 cells. The dose screening 
for cotinine shows that the use of a dose smaller or equal 
to 1mM does not induce modifications of the cell 
viability. Thus, following the dose screening, the 
concentration of 2mM of cotinine was selected for the 
further study of the cell proliferation. 
 
 
 
Figure 3. The viability of the MRC-5 cells 
treated for 24 h with D1 = 2 mM, D2 = 1 mM, 
D3 = 750 µM, D4 = 500 µM, D5 = 100 µM, 
D6 = 10 µM si D7 = 1 µM cotinine in culture 
medium      
 
Evaluation of proliferative potential 
The evaluation of proliferative potential has shown 
that non-treated control MRC-5 cells proliferate 
significantly (p<0.0001) in culture for 48h (Figure 4). 
Once exposed to the treatment with 1mM nicotine, the 
proliferative potential of the MRC-5 cells is inhibited, 
but we did not detect statistically significant changes 
between the viability of the cells treated with 1 mM 
nicotine for 24h and for 48h.   
In terms of treatment with 2 mM cotinine, the 
proliferative potential of the MRC-5 cells is inhibited 
compared to the non-treated control, with statistically 
significant differences (p<0.05) between the viability of 
the cells treated with cotinine for 24h and 48h (Figure 
4). 
 
 
Figure 4. The proliferative potential of MR-5 
cells treated for 24h and 48h with 1 mM 
ncotine or 2 mM cotinine (Nic = Nicotine; Cot 
= Cotinine)  
*** p<0.0001 control 48h versus control 24h; 
* p<0.05 cotinine 48h versus cotinine 24h) 
The results indicated that the MRC-5 cells treated 
with 1mM nicotine do not proliferate after 48h of 
treatment, in contrast to those treated with 2 mM 
cotinine that retain some weak proliferative potential if 
treated for 48h. 
 
Discussions 
Evidence confirms harmful effects of tobacco use 
and nicotine. Smoking is demonstrated as a risk factor 
for various types of cancer, including lung, oral cavity, 
or breast cancer. Nicotine has been shown to have 
tumor-promoting activity. In addition, growing 
evidence suggests that the use of tobacco can reduce the 
efficacy of cancer medicines and may increase the risk 
of recurrence, while migration to other geographical 
areas is able to influence the cancer incidence (19).  
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In recent years, research has provided findings 
regarding the mechanism of nicotine toxicity.  
Furthermore, evaluation of the toxicological profile of 
cotinine, the main metabolite of nicotine, is under 
current investigation. Controversy over the toxicity of 
cotinine continues. Cotinine is less lipophilic than 
nicotine and has been found to be less cytotoxic than 
nicotine on fibroblast (HFF), melanoma (SK-Mel/27), 
and hepatoma (HepG2) cell lines (20). Nicotine and 
cotinine were not cytotoxic to Chinese hamster ovary 
(CHO) cells (21). 
The present study evaluated the toxicity of nicotine 
and its metabolite cotinine on normal human lung cell 
line MRC-5. Limited data are published with respect to 
the cytotoxic effects of nicotine and cotinine on normal 
cells. Our study investigated the cytotoxic potential of 
nicotine compared to cotinine on MRC-5 human lung 
fibroblast cell line by using the MTT assay. 
Our overall results are in line with studies 
investigating the cytotoxicity of nicotine in various in 
vitro systems. Nicotine, at a concentration of 1μM, was 
shown to exert a minor effect on the viability of MRC-5 
normal fibroblasts, while the proliferation of both 
human lung cancer cell lines A549 and SKMES-1 (13% 
for A549 and 14% for SKMES-1) was slightly enhanced 
(22).  
The treatment of MRC-5 cells with nicotine-free 
tobacco extract (1 mg/mL, but no 0.1 mg/mL) reduced 
(p < 0.05) the viability of MRC-5 cells by 42%, 
indicating that components other than nicotine in 
tobacco leaves exhibited cytotoxic effect (23).  
Current reports indicate that the toxic effect exerted 
in vitro by nicotine depends on the type of the cell tested. 
At a concentration higher than 2.5 mM, nicotine 
inhibited cell proliferation in human periodontal 
ligament fibroblast (PDLFs) (24), suggesting that 
nicotine may contribute to the progression of 
periodontal disease. 
It has been demonstrated that nicotine is not 
cytotoxic on MCF-7 human breast cancer cells and KB-
3.1 human nasopharyngeal carcinoma cells. 
Furthermore, pretreatment with nicotine (10 µM) 
determined significant protection to MCF-7 cells and 
KB-3.1 cells treated with doxorubicin (25).  
The results of our study indicate that high nicotine 
concentrations (2 mM) induced marked cell death (about 
50%) in MRC-5 cell line. Similar results have been 
reported in experiments on alveolar cell line (A549). 
Nicotine was shown to act in a concentration-dependent 
manner on A549 lung cells and concentrations 
beginning with 4mM showed a significant toxic effect 
on the cell viability (26). 
Cotinine was less cytotoxic than nicotine on MRC-
5 cell line. The results indicate that the MRC-5 cells 
treated with 1mM nicotine do not proliferate after 48h 
of treatment, in contrast to those treated with 2 mM 
cotinine that retain weak proliferative potential if treated 
for 48h. 
The present study demonstrated that, at 
physiologically relevant concentrations, both nicotine 
and cotinine would have no significant toxic effect on 
MRC-5 pulmonary fibroblasts. High concentrations 
decreased the cell viability, and cotinine was proved to 
be less toxic than nicotine in MRC-5 cells. In contrast to 
nicotine treatment, cells treated with cotinine continue 
to proliferate after 48h incubation period. 
 
Conclusions 
Our data indicate that, at concentrations similar to 
those reported in the bloodstream of smokers, nicotine 
and cotinine have not been shown to be cytotoxic on the 
tested MRC-5 normal human lung cell line. 
The viability of the MRC-5 cells treated with higher 
concentration of nicotine or cotinine was decreased, and 
nicotine was shown to be more toxic than cotinine.  
The results of the study provide additional 
information on the toxicity of cotinine and nicotine on 
normal cells. 
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